Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers.

Dr. Andrea Small-Howard has overseen the day-to-day operations of the company in her role as President for the past three years. She was promoted to CEO, CFO and Chairman of the Board as a part of their succession plan, which was created due to the failing health of Mr. John Poss. GB Sciences is saddened at the passing of Mr. John Poss. Mr. Poss had battled through serious health issues and had served the company very well since 2015. Fortunately, Mr. Poss had spent years preparing Dr. Small-Howard for her expanded role as CEO, CFO and Chairman, which roles fell to her upon the passing of Mr. Poss on July 10, 2024. In addition, Dr. Small-Howard will continue to leverage her expertise in bringing novel biopharmaceutical products from ideation through commercialization. Dr. Small-Howard is a founding board member of GB Sciences, and she is the architect of the strategic vision at GB Sciences to make safe, effective, and standardized cannabinoid medicines available to patients where their use can be supported with rigorous evidence.

GB Sciences is grateful to Mr. John Poss for his many years of service. He joined GB Sciences as the chief financial officer in August of 2015, prior to serving as GB Sciences' CEO and Chairman for eight years.